BRPI0419213A - Dry forms of aqueous solubilized bile acid dosage formulation: preparation and uses of these - Google Patents
Dry forms of aqueous solubilized bile acid dosage formulation: preparation and uses of theseInfo
- Publication number
- BRPI0419213A BRPI0419213A BRPI0419213-3A BRPI0419213A BRPI0419213A BR PI0419213 A BRPI0419213 A BR PI0419213A BR PI0419213 A BRPI0419213 A BR PI0419213A BR PI0419213 A BRPI0419213 A BR PI0419213A
- Authority
- BR
- Brazil
- Prior art keywords
- bile acid
- aqueous
- dry forms
- preparation
- dosage formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title abstract 6
- 239000003613 bile acid Substances 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 3
- 229920002472 Starch Polymers 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000002244 precipitate Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 235000019698 starch Nutrition 0.000 abstract 2
- 239000008107 starch Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 150000001412 amines Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000012084 conversion product Substances 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
FORMAS SECAS DE FORMULAçãO DE DOSAGEM DE AGIDO BILIAR SOLUBILIZADA AQUOSA: PREPARAçãO E USOS DESTAS. Composições para usos farmacêuticos e outros que compreendem soluções aquosas claras de ácidos biliares que não formam quaisquer precipitados detectáveis sobre as faixas selecionadas de valores de pH da solução aquosa e métodos de preparar tais soluções são descritas. Composições da descrição podem compreender água; um ácido biliar na forma de um ácido biliar, sal de ácido biliar ou ácido biliar conjugado com uma amina por uma ligação de amida; e qualquer um ou ambos os produtos de conversão de amido solúvel aquoso e um polissacarídeo de não amido solúvel aquoso. A composição permanece na solução sem formar um precipitado sobre uma faixa de todos os valores de pH obteníveis em um sistema aquoso. A composição, de acordo com algumas modalidades, pode também conter um composto farmacêutico em uma quantidade farmaceuticamente eficaz. A descrição também fornece formas secas de formulações de ácido biliar solubilizadas aquosas primárias e métodos de preparar tais formas secas.DRIED FORMS OF WATER SOLUBILIZED BILARY AGE DOSAGE FORMULATION: PREPARATION AND USE OF THESE. Pharmaceutical and other compositions comprising clear aqueous solutions of bile acids which do not form any detectable precipitates over the selected pH range of the aqueous solution and methods of preparing such solutions are described. Compositions of the description may comprise water; a bile acid in the form of a bile acid, bile acid salt or bile acid conjugated to an amine by an amide bond; and either or both of the aqueous soluble starch conversion products and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a range of all pH values obtainable in an aqueous system. The composition, according to some embodiments, may also contain a pharmaceutical compound in a pharmaceutically effective amount. The description also provides dry forms of primary aqueous solubilized bile acid formulations and methods of preparing such dry forms.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2004/039507 WO2006057637A1 (en) | 2004-11-24 | 2004-11-24 | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0419213A true BRPI0419213A (en) | 2007-12-18 |
Family
ID=34959579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0419213-3A BRPI0419213A (en) | 2004-11-24 | 2004-11-24 | Dry forms of aqueous solubilized bile acid dosage formulation: preparation and uses of these |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1819318A1 (en) |
| JP (1) | JP2008521800A (en) |
| CN (1) | CN101065110A (en) |
| AU (1) | AU2004325203A1 (en) |
| BR (1) | BRPI0419213A (en) |
| CA (1) | CA2588168A1 (en) |
| WO (1) | WO2006057637A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772220B2 (en) | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| US7145125B2 (en) | 2003-06-23 | 2006-12-05 | Advanced Optical Technologies, Llc | Integrating chamber cone light using LED sources |
| ES2339790T3 (en) | 2004-08-30 | 2010-05-25 | Seo Hong Yoo | NEUOPROTECTOR EFFECT OF UDCA SOLUBILIZED IN FOCAL ISCHEMICAL MODEL. |
| DE602005027727D1 (en) * | 2004-10-15 | 2011-06-09 | Seo Hong Yoo | COMPOSITIONS TO REDUCE THE TOXICITY OF CISPLATIN, CARBOPLATIN AND OXALIPLATIN |
| CN106075449A (en) | 2005-07-14 | 2016-11-09 | 尼奥塞蒂克斯公司 | Enhanced lipolytic formulation for the sustained release of regional adipose tissue treatment |
| EP2367554A4 (en) | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | BILIARY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF OBESITY AND DIABETES |
| US8318663B2 (en) | 2008-11-26 | 2012-11-27 | Satiogen Pharmaceuticals, Inc. | Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent |
| JP5420946B2 (en) | 2009-03-23 | 2014-02-19 | 富士フイルム株式会社 | Minoxidil aqueous composition containing bile acids |
| US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
| WO2011075539A2 (en) * | 2009-12-18 | 2011-06-23 | Satiogen Pharmaceuticals, Inc. | Treatment of obesity or diabetes with bile acid sequestrants |
| EP4137137A1 (en) | 2010-05-26 | 2023-02-22 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| CN101843823B (en) * | 2010-05-27 | 2014-04-09 | 宫兆荣 | Anti-flu injection and preparation method thereof |
| BR112013012994A2 (en) | 2010-11-24 | 2016-09-13 | Lithera Inc | long-acting, lipophilic and selective beta-agonist monotherapeutic formulations and methods for the cosmetic treatment of contour adiposity and overhang |
| JP6217938B2 (en) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | Bile acid recirculation inhibitors for the treatment of cholestatic liver disease in children |
| EA038594B1 (en) | 2011-10-28 | 2021-09-21 | Шайр Хьюман Дженетик Терапис, Инк. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| KR20180036580A (en) | 2016-09-30 | 2018-04-09 | 주식회사 유스바이오팜 | Composition for prevention or treatment of inflammatory skin diseases or severe pruritus comprising the aqueous solubilized ursodeoxycholic acid |
| KR102252450B1 (en) * | 2017-02-09 | 2021-05-14 | 주식회사 아미코젠파마 | Composition for prevention or treatment of visual disorders comprising ursodeoxycholic acid |
| CN108272824A (en) * | 2018-03-11 | 2018-07-13 | 张显英 | A kind of bile extraction process |
| KR102297982B1 (en) * | 2019-09-27 | 2021-09-02 | 건양대학교 산학협력단 | A method for predicting using kits capable of predicting inhibition of rumen microorganism using bile acid |
| CN112138026A (en) * | 2020-10-28 | 2020-12-29 | 中南民族大学 | Application of a kind of bear bile powder in anti-intoxication and prevention of acute alcoholic fatty liver |
| KR20250100660A (en) | 2022-10-25 | 2025-07-03 | 베라더믹스 인코포레이티드 | Composition and method of use of modified release minoxidil |
| CN115671408A (en) * | 2022-10-29 | 2023-02-03 | 金傅(北京)医疗科技有限公司 | Substance capable of avoiding granulation tissue hyperplasia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61171421A (en) * | 1985-08-23 | 1986-08-02 | Yamanouchi Pharmaceut Co Ltd | Production of stable prostaglandin e preparation |
| JPS62153220A (en) * | 1985-12-27 | 1987-07-08 | Tokyo Tanabe Co Ltd | Water-based bile acid agent for internal use |
| JPH0747539B2 (en) * | 1986-10-22 | 1995-05-24 | 東京田辺製薬株式会社 | Bile acid solid formulation |
| JPS63243031A (en) * | 1987-03-28 | 1988-10-07 | Tokyo Tanabe Co Ltd | Solid pharmaceutical of bile acid |
| JPH0624991A (en) * | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | Ursodesoxycholic acid depot |
| US5578304A (en) * | 1992-06-22 | 1996-11-26 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
| IT1255968B (en) * | 1992-11-27 | 1995-11-17 | PHARMACEUTICAL COMPOSITIONS CONTAINING URSODESOXICOLIC ACID | |
| LU88375A1 (en) * | 1993-07-12 | 1994-04-01 | Michel Urso Prof Medecin Et Ch | Energy product stimulating male potency |
| CN100558407C (en) * | 2000-02-04 | 2009-11-11 | 柳署弘 | Preparation of clear aqueous dosage forms containing bile acids |
-
2004
- 2004-11-24 EP EP04812094A patent/EP1819318A1/en not_active Withdrawn
- 2004-11-24 BR BRPI0419213-3A patent/BRPI0419213A/en not_active IP Right Cessation
- 2004-11-24 JP JP2007543006A patent/JP2008521800A/en active Pending
- 2004-11-24 CA CA002588168A patent/CA2588168A1/en not_active Abandoned
- 2004-11-24 WO PCT/US2004/039507 patent/WO2006057637A1/en not_active Ceased
- 2004-11-24 CN CNA2004800444670A patent/CN101065110A/en active Pending
- 2004-11-24 AU AU2004325203A patent/AU2004325203A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008521800A (en) | 2008-06-26 |
| AU2004325203A1 (en) | 2006-06-01 |
| CA2588168A1 (en) | 2006-06-01 |
| EP1819318A1 (en) | 2007-08-22 |
| WO2006057637A1 (en) | 2006-06-01 |
| CN101065110A (en) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0108080A (en) | Preparation of aqueous clear bile acid solution dosage forms | |
| BR9912395A (en) | Preparation of dosage forms of clear aqueous solution with bile acids | |
| BRPI0513508A (en) | insulin-oligomer conjugates, formulations and uses of these | |
| BR112012004051A8 (en) | aqueous concentrate formulation, use of aqueous concentrate formulation and method to control unwanted vegetation | |
| BRPI0611400B1 (en) | formulations containing mucus-adhesive xyloglycan useful in medical devices and pharmaceutical formulations | |
| WO2011079234A3 (en) | Highly permeating terbinafine formulation for treating onychomycosis | |
| BR0113663A (en) | Pectin Film Compositions | |
| CA2696335A1 (en) | Gel containing pirfenidone | |
| TR200003158T2 (en) | Gelling pharmaceutical compositions | |
| BR0113496A (en) | A compound or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, use thereof, method for producing a cell cycle inhibitory effect (anti-cell proliferation) in a warm-blooded animal, and pharmaceutical composition. | |
| HRP20130071T1 (en) | Improved testosterone gel and method of use | |
| BRPI0508579A (en) | compound, pharmaceutical composition, and use of a compound | |
| UA93995C2 (en) | Pharmaceutical compositions for treating burns and process for the preparation thereof | |
| BRPI0515860B8 (en) | tetralin and indane derivatives, their uses, and pharmaceutical composition | |
| AU2016418505B2 (en) | Solid cleansing compositions with taurine and methods thereof | |
| RU2006101686A (en) | COMPOSITIONS FOR LOCAL APPLICATION RESTORING THE STRUCTURE OF NAILS | |
| BRPI0411702B8 (en) | use of hyaluronic acid to prepare compositions for the treatment of thrush of the oral cavity | |
| HRP20140676T1 (en) | Formulations of deoxycholic acid and salts thereof | |
| ITMI20071724A1 (en) | ANTIVIRAL TOPIC FORMULATIONS IN THE FORM OF BIOADESIVE GEL | |
| BRPI0412453A (en) | ascorbic acid or a physiologically acceptable salt thereof | |
| HRP20110698T1 (en) | Nucleic acid complex and nucleic acid delivery composition | |
| RU2018125252A (en) | Synergistic combination of pyrrolidone-carboxylic acid and / or its salts and hyaluronic acid and / or its salts for use in the treatment and / or prevention of dryness and irritation of mucous membranes | |
| US20150174245A1 (en) | Transparent gel | |
| JP2010521519A5 (en) | ||
| HRP20140504A2 (en) | Stabilized formulation of ortho-silica acid, preparation and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S) |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |